Lotti

Lotti is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for ocular diseases, specifically targeting the ocular surface and anterior segment. Founded by industry veterans from Santen Pharmaceutical, the company leverages extensive expertise in ophthalmic drug discovery to address significant unmet medical needs. Lotti's lead therapeutic candidate, LT-001, is a novel small molecule currently being evaluated in Phase 2 clinical trials for the treatment of dry eye disease. The company's strategy involves optimizing secretagogue mechanisms to restore tear film stability and improve patient outcomes. Headquartered in Emeryville, California, Lotti is backed by leading life science venture capital firms, including Avalon BioVentures.